Saroglitazar: India's Answer to Diabetic Dyslipidemia

Incidence of dyslipidemia among people suffering from diabetes is shooting up each year around the globe. A novel target to control this disorder has agonistic activity on peroxisome proliferator-activated receptors (PPAR)-α and PPAR-γ receptors simultaneously. While the α form has lipid lowering effects, γ leads to lowering in blood glucose. Saroglitazar (Lipaglyn), developed by Zydus Cadila, first new chemical entity (NCE) discovered and developed indige-nously by an Indian Pharma Company, has agonistic activity on both PPAR-α and PPAR-γ receptors. Unlike other glitazars that were discontinued during their development, saroglitazar enjoys a high benefit-to-risk ratio. It is indicated for the treatment of diabetic dyslipidemia and hypertriglyceridemia with Type 2 diabetes mellitus not controlled by conventional therapy. Dose recommended for Lipaglyn is 4mg once a day.